Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis.

Cancer Med · 2023 · PMC10501238 · PMID 37403746

Europe PMC DOI

hedged sentences

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

did not reach statistical significancep = 0.072so close (0.05 < p ≤ 0.1)

There was a trend towards a longer median OS with eribulin combination therapy (median not reached) compared with eribulin monotherapy (12.1 months, 95% CI 8.6–15.7) but this did not reach statistical significance ( p = 0.072, hazard ratio 0.531; Figure 3B ).

also in 111,027 other papers

approached significanceno p-value reported

Interestingly, a systematic review and meta‐analysis of eribulin in locally advanced or MBC found that eribulin in third‐line or beyond was associated with a significant OS benefit versus non‐eribulin therapy, but the benefit only approached significance in first/second line, 28 which indicated that further evidence from large randomized trials was required to full assess eribulin versus paclitaxel as first‐ or second‐line therapy.

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.